Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present preclinical data on its ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Pharmacological strategies to enhance the activity of Cbl-B or GRAIL do currently not exist, but several strategies can be applied to boost the activity of these E3 ligases. For example, small ...

NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK ... and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that ...

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are covering the firm, Marketbeat ...

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price decreased by The Goldman Sachs Group from $2.25 to $1.75 in a research note published on Thursday morning,Benzinga ...

Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

This diverse class of targets has historically been difficult to drug due to small molecule chemistry limitations ... isomerases, and ligases. Metal ions, including magnesium, zinc, iron ...